Tarsus Pharmaceuticals Earnings
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$-1.49
Tarsus Pharmaceuticals earnings summary
Tarsus Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $-1.49. In its most recent report on Aug 6, 2026 (Q2 2026), TARS posted EPS of $-0.43. Revenue for the quarter was $173.9 million.
Across the last 16 reports, TARS shares moved an average of 5.7% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
TARS earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.43 | — | +6.8% |
| May 6, 2026 | — | $-0.16 | — | +2.1% |
| Feb 23, 2026 | — | $-0.17 | — | -3.0% |
| Nov 4, 2025 | — | $-0.30 | — | +6.8% |
| Aug 6, 2025 | — | $-0.48 | — | +13.3% |
| May 1, 2025 | — | $-0.64 | — | -5.5% |
| Feb 25, 2025 | — | $-0.57 | — | +4.5% |
| Nov 13, 2024 | — | $-0.61 | — | +7.6% |
| Aug 8, 2024 | — | $-0.88 | — | -4.3% |
| May 8, 2024 | — | $-1.01 | — | +3.4% |
| Feb 27, 2024 | — | $-1.29 | — | -9.8% |
| Nov 9, 2023 | — | $-1.28 | — | +8.0% |
| Aug 10, 2023 | — | $-1.17 | — | +1.8% |
| May 9, 2023 | — | $-0.88 | — | -2.0% |
| Mar 17, 2023 | — | $-0.46 | — | -6.5% |
| Nov 9, 2022 | — | $-0.84 | — | -6.6% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.